"Overall, we found that Prostate Health Index above 55 preoperatively was associated with any incidental prostate cancer as well as clinically significant prostate cancer," says Eric Li, MD.
In this video, Eric Li, MD, highlights findings from his study, “Prostate Health Index is associated with Incidental Prostate Cancer Detection at Time of Holmium Laser Enucleation of the Prostate,” which will be presented at the 2023 Annual American Urological Association Conference in Chicago, Illinois. Li is a urology resident at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Video Transcript:
These are patients who had prostate cancer found at the time of holmium enucleation of the prostate, which is a procedure done on the prostate to help men urinate better. Historically, rates of cancer detection had been as high as 20%. Now we have these advanced screening tools such as Prostate Health Index and prostate MRI. The question is, what are the new preoperative risk factors for finding prostate cancer at the time of HoLEP, or holmium enucleation of the prostate. The reason why this is relevant is because if we detect clinically significant prostate cancer preoperatively these patients may actually benefit from radical prostatectomy rather than a HoLEP. Overall, we found that Prostate Health Index above 55 preoperatively was associated with any incidental prostate cancer as well as clinically significant prostate cancer. The takeaway is that these patients should undergo biopsy to make sure that they don't have cancer that would require other treatment before going HoLEP.
This transcription has been edited for clarity.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).